Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SONIC: Sonrotoclax Ramp-Up in CLL, SLL, and MCL
NCT06839053Phase 2Recruiting
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Jun 2025
- Primary completion
- Aug 2028
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label trial of sonrotoclax in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and mantle cell lymphoma (MCL) (2 arms), sponsored by Fred Hutchinson Cancer Center. Primary endpoints: Incidence of adverse events at Day 12, Percentage of patients who reach an 80mg dose of sonrotoclax at Day 4 and 1 more. Started Jun 2025; status: recruiting.
02
Drugs
sonrotoclax
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT06839053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06839053.